Humanwell Healthcare’s Yuchan Granules enter phase II trial for diabetic kidney disease

Humanwell Healthcare Group’s wholly-owned subsidiary, Wuhan Humanwell Innovative Drug R&D Center Co., Ltd., has announced that its Yuchan Granules have entered phase II clinical trials. The trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of Yuchan Granules for diabetic kidney disease with overt albuminuria. The primary objective is to assess effectiveness, safety, and explore dosage for future phase III studies.

Yuchan Granules, derived from an experience-based prescription from a Shanghai University of Traditional Chinese Medicine affiliated hospital, is classified as a Class 1.1 innovative traditional Chinese medicine. Its indicated function is to "tonify the spleen and kidney, promote blood circulation, and resolve water retention," targeting protein in the urine from diabetic kidney disease.

The total R&D investment for Yuchan Granules to date is approximately RMB9,000,000. Current market data from 2024 indicates that similar approved traditional Chinese medicines for diabetic kidney disease had combined sales of approximately RMB80,000,000 in China.